Your email has been successfully added to our mailing list.

×
0.0468227424749163 0.110367892976589 0.110367892976589 0.103645484949833 0.103678929765886 0.080267558528428 -0.0100334448160536 0.00913043478260865
Stock impact report

Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose Intolerance

RITTER PHARMACEUTICALS (RTTR) 
Last ritter pharmaceuticals earnings: 8/14 05:11 pm Check Earnings Report
US:NASDAQ Investor Relations: ritterpharmaceuticals.com/investors
Company Research Source: GlobeNewswire
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of the first FDA-approved treatment for lactose intolerance, today announces that it has signed an agreement with the clinical research organization (CRO) Medpace to conduct the first of two pivotal Phase 3 clinical trials for RP-G28 in patients with lactose intolerance (LI). “Our team has worked diligently to identify and select the right CRO partner to execute our pivotal Phase 3 clinical trial for RP-G28,” said Andrew J. Ritter, co-founder and president of Ritter Pharmaceuticals, Inc. “Medpace is an established, highly regarded full-service Phase I-IV CRO with expertise in numerous therapeutic areas that is focused on supporting the biotech and pharmaceutical industry. It is a scientifically-driven Show less Read more
Impact Snapshot
Event Time:
RTTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RTTR alerts
Opt-in for
RTTR alerts

from News Quantified
Opt-in for
RTTR alerts

from News Quantified